Plain-English translation of NCT05892718 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called in people with advanced cancers that have stopped responding to standard treatments. The medication works by boosting your immune system to recognize and attack cancer cells. Researchers want to find the right dose and understand how safe and effective this treatment is.
Many people with advanced cancers run out of effective treatment options when standard therapies stop working. This medication uses a new approach to wake up the immune system, offering hope to patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (through an IV in your arm) at a medical center. The study starts with small doses and gradually increases them in different groups to find the safest effective dose. You will have regular visits for blood tests, imaging scans, and physical exams to monitor how you are responding and check for any side effects. You will continue treatment until the cancer progresses, you experience unacceptable side effects, or the study ends.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
United States
China